About Cullinan Oncology
Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the Cullinan dry lab as well as external collaborators, Cullinan’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.
Co-Founder and CSO: Patrick Baeuerle, PhD
CEO: Owen Hughes
CSO: Leigh Zawel, PhD
Please click here for Cullinan Oncology's approach.
26 articles with Cullinan Oncology
Cullinan Oncology Receives FDA Clearance of Investigational New Drug (IND) Application for CLN-619, a Novel MICA/B-targeted Antibody for the Treatment of Solid Tumors
Cullinan Oncology, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared Cullinan MICA’s IND application for CLN-619.
6/14/2021A busy week for clinical trial news as the ASCO meeting wrapped up and the European Hematology Association 2021 Virtual Congress began. Read on for more.
Cullinan Oncology Receives Investigational New Drug (IND) Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific Antibody for the Treatment of Relapsed/Refractory AML
Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today announced that the U.S. Food and Drug Administration (FDA) has cleared Cullinan Florentine’s IND application for CLN-049, a FLT3 x CD3 bispecific antibody for the treatment of relapsed/refractory acute myeloid leukemia (AML).
Cullinan Oncology, Inc., an oncology company seeking to drive shareholder returns by focusing on the patient, announced that it will provide a clinical update on CLN-081 during a webinar on Friday, June 4th, 2021 at 10:30 am ET.
Continued advancement of broad portfolio, highlighted by initiation of Phase 2a dose expansion of Cullinan Pearl in NSCLC patients with EGFRex20ins mutations
Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) announced today that the company’s Chief Financial Officer, Jeff Trigilio, will present at the upcoming 20 th Annual Needham Virtual Healthcare Conference.
Pipeline Progress: Clinical and preclinical programs continue to advance, with encouraging initial Cullinan Pearl data and additional INDs to be filed in 2021 for immuno-oncology assets Cullinan Florentine and Cullinan MICA
Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies, today announced that the company’s Chief Executive Officer, Owen Hughes, will present at the upcoming H.C. Wainwright Global Life Sciences Conference.
12/23/2020A roundup of the latest biopharma companies scooping up cash through IPOs and financing rounds.
Cullinan Oncology, LLC, a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, announced today the closing of an oversubscribed $131.2 million Series C financing. The financing was led by Foresite Capital with participation from additional new investors: Boxer Capital of Tavistock Group; Eventide Asset
Cullinan Oncology is proud to announce that its Chief Medical Officer, Jon Wigginton MD, has been honored by the Society for Immunotherapy of Cancer as a recipient of its 2020 Visionary Legacy Award.
Cullinan Oncology, LLC announced today the appointment of Jeffrey Trigilio as the company’s Chief Financial Officer. In addition to his primary financial responsibilities, Jeff will play an important role across many facets of the business, including business development, project management and investor relations. “We are fortunate to have someone of Jeff’s caliber join Cullinan at this stage of the company’s devel
Cullinan Pearl Announces Presentation of Preliminary Safety and Efficacy of CLN-081 in EGFR Exon 20 NSCLC Patients at ESMO Virtual Congress 2020
Cullinan Pearl, a Cullinan Oncology company, today announced that an abstract detailing the ongoing Phase 1/2a clinical trial evaluating CLN-081 for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer (NSCLC) will be presented as a poster presentation at the ESMO Virtual Congress 2020. Poster Title : Preliminary Safety and Activity of CLN-081 in NSCLC with EGFR Exon 20 Insertion Mutations (I
Cullinan Oncology, German Cancer Research Center (DKFZ) and the University of Tübingen Announce the Formation of Cullinan Florentine to Develop CLN-049, a Novel Bispecific Antibody for AML
Cullinan Oncology, LLC, the German Cancer Research Center and the Eberhard Karls University of Tübingen, Faculty of Medicine (University of Tübingen), Germany, today announced the formation of Cullinan Florentine, a company focused on developing a novel FLT3 x CD3 bispecific antibody for the treatment of patients with acute myeloid leukemia (AML). This antibody has been developed in Tübingen wit
Cullinan Oncology Launches Cullinan Amber to Pioneer Next-Generation Cytokine Fusion Proteins for Cancer Therapy
Cullinan Oncology, LLC today announced the launch of Cullinan Amber, a company focused on developing a next generation immuno-oncology platform to enhance the therapeutic window of immune-stimulatory cytokine combinations for the treatment of cancer. Cullinan Amber has acquired an exclusive license from the Massachusetts Institute of Technology for technology based on the seminal work of K. Dane Wittrup, the C. P. Dubbs
Cullinan Oncology and PDI Therapeutics Join Forces to Bring Novel, First-In-Class Immuno-Oncology Antibody into the Clinic through a $26M Series A Financing
Cullinan Oncology LLC and PDI Therapeutics, a portfolio company of Avalon Ventures, today announced a collaboration to bring CLN-619, a first-in-class monoclonal antibody reinvigorating the MICA/NKG2D axis into human clinical testing. As a result of the transaction, Cullinan MICA, Inc., a Cullinan Oncology portfolio company, will assume operational control of the asset. “We have been very imp
Cullinan Oncology, LLC announced today the closing of a $98.5 million Series B financing, which will be used to support ongoing clinical trials across its small molecule and biologics portfolio. New institutional investors and family offices participated in the financing alongside o
Cullinan Oncology Announces First Patients Dosed with Drug Candidates from Cullinan Apollo and Cullinan Pearl
Cullinan Oncology, LLC announced the initiation of dosing with VK-2019, Cullinan Apollo’s first-in-class EBNA1 inhibitor for Epstein Barr Virus positive cancers and CLN-081, Cullinan Pearl’s novel epidermal growth factor tyrosine kinase inhibitor for non-small cell lung cancer.
The EMBL has presented Baeuerle with the 2019 Lennart Philipson Award for his pivotal role in developing cancer immunotherapies.
Taiho Pharmaceutical and Cullinan Oncology Establish Collaboration to Develop TAS6417, Novel EGFR Tyrosine Kinase Inhibitor
FIH Study in EGFR Exon 20 Insertions Will Commence in 2019